Steatohepatitis/Metabolic Liver Disease News

Lipocine announced top-line interim results from an ongoing study of LPCN 1144, an oral prodrug of bioidentical testosterone designed for the treatment of nonalcoholic steatohepatitis, according to a press release.

Barriers to initiating a Mediterranean diet — shown to improve liver health in patients with nonalcoholic fatty liver disease — included an obesogenic environment, life stressors, and demand for convenience, according to a study published in Clinical Gastroenterology and Liver Disease.

ChemomAb dosed the first patient in a phase 1b repeated-dose clinical trial of CM-101 for treating patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release.

Researchers continue efforts to study and develop safe and effective therapeutics to treat nonalcoholic fatty liver disease and its progressive form, nonalcoholic steatohepatitis, including several collaborative efforts between clinical development companies and societies.

Crestor safely and effectively managed NGM282-associated LDL cholesterol elevation, according to a study published in Journal of Hepatology.

Results of a phase 1 study of repeated and increasing doses of CER-209 in patients with a high risk for nonalcoholic fatty liver disease or nonalcoholic steatohepatitis showed a favorable safety and tolerance profile, according to a press release from Cerenis Therapeutics.

Gilead Sciences and Yuhan Corporation have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of advanced fibrosis due to nonalcoholic steatohepatitis, according to a press release.

Merck has licensed NGM Biopharmaceuticals’ NGM313, an investigational monoclonal antibody agonist of the beta-Klotho/fibroblast growth factor receptor 1c that is currently being evaluated for the treatment of nonalcoholic steatohepatitis and diabetes type 2, according to a press release.

Regular vigorous physical activity reduced the risk for hepatocellular carcinoma by approximately 45%, according to recently published data.

Researchers observed significant fibrosis in more than one-third of patients with hepatitis B and HIV coinfection undergoing long-term combination antiretroviral therapy with viral suppression, according to a study published in American Journal of Gastroenterology.